相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
E. Rouits et al.
BRITISH JOURNAL OF CANCER (2008)
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
D. M. Kweekel et al.
BRITISH JOURNAL OF CANCER (2008)
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
Chun-Yu Liu et al.
CANCER (2008)
Clinical and pharmacogenetic factors associated with irinotecan toxicity
Dinemarie Kweekel et al.
CANCER TREATMENT REVIEWS (2008)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A. Ruzzo et al.
PHARMACOGENOMICS JOURNAL (2008)
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Matthew T. Seymour et al.
LANCET (2007)
Distribution of the UGT1A1 28 polymorphism in Caucasian and Asian populations in the US:: a genomic analysis of 138 healthy individuals
Jackie Yao Liu et al.
ANTI-CANCER DRUGS (2007)
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping
Federico Innocenti et al.
PHARMACOGENOMICS (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
A Font et al.
INVESTIGATIONAL NEW DRUGS (2003)
分享论文
